Today: 19 May 2026
Browse Category

NASDAQ:GRAL 3 October 2025 - 27 February 2026

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Stock Rockets on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL shares surged 14% to a record $85.35 on Oct. 16 after Samsung agreed to invest $110 million and partner on cancer test rollout in Asia. New trial data showed Galleri’s blood test boosted early cancer detection seven-fold in a 25,000-patient study. GRAIL secured $325 million in fresh funding, extending its cash runway into 2030. Analysts remain cautious, with a consensus Hold rating and a $57 price target.
20 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL shares surged 13–14% to a record $85.35 on Oct. 16 after announcing a $110 million equity deal with Samsung and plans to bring its Galleri cancer test to Asia. New trial data at ESMO showed Galleri doubled early cancer detection versus routine screening. Despite gains, most analysts rate GRAL a “Hold” with an average target below current prices. Q2 revenue rose 11% to $35.5M; net loss narrowed to $114M.
18 October 2025
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAL stock surged 14% to a record $86 after Samsung agreed to invest $110 million and help launch GRAIL’s Galleri cancer blood test in Asia. New trial data showed the test doubled early cancer detection rates. GRAIL shares are up over 300% this year, valuing the company at $2.7 billion. Most analysts rate the stock “Hold,” with average targets well below current prices.
17 October 2025
····
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL shares jumped 13.6% to close at $85.82 on Oct. 16 after announcing a $110 million equity investment and distribution deal with Samsung C&T and Samsung Electronics. Samsung C&T will exclusively distribute GRAIL’s Galleri cancer test in South Korea, with possible expansion to Japan and Singapore. GRAL’s market cap rose to about $2.7 billion. Most analysts maintain a Hold rating despite the stock’s 321% year-to-date gain.
16 October 2025
···
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAL shares surged to $69.14 intraday on Oct 3, up nearly 6.8% and about 248% year-to-date. Market cap reached $2.3–2.5 billion, a 472% jump since mid-2024, despite ongoing losses and negative EPS. Wall Street consensus remains “Hold” with a $31.50 average price target, far below current levels. Investors await new PATHFINDER 2 trial data at ESMO Congress later this month.
3 October 2025
···

Stock Market Today

  • Coffee Prices Climb as ICE Inventories Hit Lows Amid Supply Concerns
    May 19, 2026, 5:13 PM EDT. Coffee prices surged with July arabica up 2.25% and robusta rising 1.18% on Tuesday as inventories on the Intercontinental Exchange (ICE) shrank to multi-month lows. Arabica stocks dropped to a 2.75-month low of 458,735 bags, while robusta reached a two-year low of 3,631 lots. The dip followed a three-week selloff that pushed prices into oversold territory, triggering technical buying and fund short-covering. Despite bullish inventory trends, expectations of a larger Brazilian coffee crop and soaring Vietnamese robusta exports weigh on prices. The United States Department of Agriculture (USDA) projects a 2% rise in global coffee production for 2025/26, with growing robusta output offsetting a decline in arabica. Ongoing disruptions like the Strait of Hormuz closure tighten supply and increase costs, supporting prices despite forecasts of a global surplus.

Latest articles

Cava’s Earnings Beat Just Put the Restaurant Slowdown Story on Notice

Cava’s Earnings Beat Just Put the Restaurant Slowdown Story on Notice

19 May 2026
Cava raised its 2026 sales and profit outlook after first-quarter same-restaurant sales jumped 9.7%, driven mostly by a 6.8% rise in guest traffic. Revenue reached $438.3 million, topping analyst estimates, while net income slipped to $23.6 million from $25.7 million a year earlier. Shares rose 6% after hours. The company now expects same-restaurant sales growth of 4.5% to 6.5% for the year.
Europe Faces Fresh LNG Worry, This Time From the US

Europe Faces Fresh LNG Worry, This Time From the US

19 May 2026
Europe is set to source about two-thirds of its liquefied natural gas from the United States in 2026, with Poland among the most reliant buyers, according to IEEFA data. Poland’s Gdańsk floating terminal project reached a new milestone, with its regasification unit expected to arrive in late 2027. U.S. LNG supplied 63% of Europe’s imports in the first quarter, up from 58% in 2025.
Alphabet’s $5B AI Cloud Push Gets Wall Street Scrutiny; Google Shares Drop

Alphabet’s $5B AI Cloud Push Gets Wall Street Scrutiny; Google Shares Drop

19 May 2026
Alphabet Class A shares fell 2.3% to $387.66 Tuesday after Google announced new Gemini AI models, paid subscription tiers, and a $5 billion Blackstone-backed AI cloud venture. The stock had traded as high as $401.71 intraday. Google also cut prices on its top AI subscription plans and introduced Gemini 3.5 Flash, but the stronger 3.5 Pro model remains unreleased.
Go toTop